Immunoglobulin heavy and light chains are produced in plasma cells and then assembled to form immunoglobulins. There are 2 types of light chains, κ and λ, which are commonly bound to the heavy chain of the immunoglobulin. However, in pathogenic states, there is often an excess production of these light chains in the unbound form, referred to as "free light chains" (FLCs). 3 Increased concentrations of either κ and/or λ FLCs are indicative of plasma cell disorders, namely, multiple myeloma (MM), Waldenstrom macroglobulinemia (WM), immunoglobulin light chain amyloidosis (AL amyloidosis), lymphocytic neoplasms, and systemic lupus erythematous (SLE) (1) .
Monitoring FLC concentrations is important for assessing FLC-associated diseases. Typically, κ and λ FLCs are measured using nephelometric or turbidimetric methods (1) . Both the Diazyme and Freelite κ and λ FLC assays use a latex-enhanced immunoturbidimetric technique. In these assays, either κ or λ FLC antigens in a serum sample will bind to the latex-coated particles labeled with either anti-λ or anti-κ FLC. As the antigenantibody reactions proceed, immune complexes are formed (see product inserts for Diazyme and Freelite). The decrease in the intensity of the incident beam of transmitted light is then measured and is proportional to the amount of FLC in the sample. FLC concentration in the sample is then interpolated from a calibration curve of known concentrations.
The Diazyme κ and λ FLC assay were recently approved by the US Food and Drug Administration (FDA). Addition of the FLC method to our automated line in the laboratory was of interest owing to greater efficiency and better turnaround time. Therefore, we verified these new assays on the Beckman Coulter UniCel DxC 800 Synchron, in addition to comparing them to the Freelite assays performed on the Roche Cobas Integra 800 chemistry analyzer previously used in our laboratory.
METHODS
Analytical performance of the Diazyme Human κ and λ assays (Diazyme Laboratories) was evaluated on Beckman Coulter UniCel DxC 800 Synchron according to pertinent CLSI guidelines (EP 5-A3, 6-A, 9-A3, 12-A). After initial calibration, the calibrators (obtained from Diazyme Laboratories) were rerun for linearity studies. For within-run precision evaluation of FLC κ and λ assays, 20 measurements of QC levels 1 and 2 (obtained from Diazyme Laboratories) were obtained. For between-run precision evaluation of FLC κ and λ assays, QC Levels 1 and 2 (obtained from Diazyme Laboratories) were ran for a minimum of 20 days. Mean, SD, and CV were determined using EP Evaluator ® Release 12.1.0.18 (Data Innovations LLC). Quality goals for performance characteristics were set based on evaluation of previous reports on FLC κ and λ assays (2-4). For the Diazyme FLC κ assay, a desirable total allowable error (TEa) was 10% and systematic error budget (SEa; bias) was 2.5% (25% of TEa). For the Diazyme FLC λ assay, TEa was 15% and SEa was 3.75% (25% of TEa).
Method comparison included quantitative evaluation by Deming regression between the Beckman Coulter DxC-Diazyme FLC platform and the Roche Cobas Integra-Freelite platform. Bias and percent bias plots were generated using EP Evaluator software. We were limited by the number of samples we could include in our method comparison because Freelite was no longer making reagents for our Roche Cobas Integra, and thus we could only use the reagents we had on hand. Qualitative evaluation (concordance analysis) of FLC κ, λ, and κ/λ ratio between both platforms was also performed. Samples were grouped as "Normal" if their values were within the manufacturer-reported reference range (RR) or "Abnormal" if their values were outside the specified RR.
For RR studies, samples were obtained from 20 ostensibly healthy individuals working in the laboratory and used for verification of manufacturer's suggested RR. These workers did not receive any formal medical evaluation of their health status before evaluation.
Statistical analysis was performed using EP Evaluator Release 12.1.0.18 (Data Innovations LLC).
RESULTS

Linearity
The Diazyme κ FLC assay was linear with an error of 1.3%, using a measured range of 0.00 -191.00 mg/L ( Fig. 1A and 1B) . The Diazyme λ FLC assay was found to be linear using a measured range of 0.00 -205.30 mg/L, with an error of 1.8% ( Fig. 1C  and 1D ).
Within-run precision
The Control Levels 1 and 2 for Diazyme κ and λ FLC assays had observed means within manufacturer suggested 2SD (Table 1) . For the Diazyme κ assay, the manufacturer's expected Control Level 1 was 13.1-19.7 mg/L (±2SD) with a mean of 16.4 mg/L and for Control Level 2, 26.5-39.7 mg/L with a mean of 33.1 mg/L. For the Diazyme λ FLC assay, the expected range for Control Level 1 was reported to be 16.6 -25.0 mg/L (±2SD) with a mean of 20.8 mg/L. For Control Level 2, the expected range for this control level was reported to be 32.1-48.1 mg/L (±2SD) with a mean of 40.1 mg/L. Overall, the Diazyme κ and λ FLC assays had good within-run precision based on the parameter of 2SD as established by manufacturer.
Between-run precision
Control Levels for Diazyme κ and λ FLC assays had observed means within manufacturer suggested 2SD and observed CV of ≤7.1% (Table 1) .
Method comparison
Quantitative comparison of the Beckman Coulter DxC-Diazyme FLC platform and the Roche Cobas Integra-Freelite platform indicated a −2.55 mg/L bias (95% CI, −6.91-1.81 mg/L) for κ FLC and a 4.54 mg/L bias (95% CI, 0.10 -8.99 mg/L) for λ FLC ( Fig. 2; Fig. 2 in the Data Supplement that accompanies the online version of this article at http:// www.jalm.org/content/vol4/issue3).
Concordance analysis of the κ FLC assay (n = 32) on both platforms showed 100% agreement for both normal and abnormal values (Fig. 3A) . "Normal" represents samples that had values within Diazyme's reported RR when the DxC-Diazyme FLC platform was used for analysis or had normal values within Freelite's manufacturer reference when the Integra-Freelite platform was used. Similarly, "Abnormal" represents samples that had values out of manufacturer's defined RR.
For the λ FLC assay (n = 28), comparison between platforms showed 95% (19/20) agreement for normal values and 75% (6/8) agreement for abnormal values (Fig. 3B) .
A comparison of the κ/λ FLC ratio (n = 28) showed 100% concordance for normal values, and 50% (9/18) concordance for abnormal values (Fig.  3C ).
Reference range verification
Of the 20 samples that were used for verifying Diazyme's κ RR, 1 sample was outside the upper limit of the Diazyme RR (RR, 2.37-20.73 mg/L; Table  2 ), and this sample was discordant between both platforms. For the λ RR verification, all samples were within the manufacturer's RR and concordant between the 2 platforms. ...................................................................................................... ....
Diazyme and 2 Freelite) were not within the manufacturer's suggested RRs and were discordant between the 2 platforms.
DISCUSSION
We assessed the accuracy and precision of Diazyme's κ and λ FLC assays on the Beckman Coulter DxC analyzer. In addition, we compared Beckman Coulter DxC-Diazyme assays to the Roche Cobas Integra-Freelite assays that have been retired in our laboratory (Table 1) . For all linearity studies, the manufacturer used CLSI EP6-A guidelines. The reported analytical measurement range (AMR) was 4.5-150 mg/L for κ FLC, with a limit of quantification (LOQ) of 4.5 mg/L. We found κ FLC to be linear within a range of 0.00 -191.00 mg/L. Thus, we can accept the manufacturer's AMR. For λ FLC, AMR was reported as 6.1-200 mg/L with a LOQ of 6.10 mg/L. We found λ FLC to For all precision studies, the manufacturer used the CLSI EP5-A protocol. For the Diazyme κ FLC assay, the manufacturer's established within-run CVs for Control Level 1 and Control Level 2 were 3.2% and 2.1%, respectively (see Diazyme Human κ FLC assay product insert). To validate the manufacturer's established precision claim, we performed a within-run study using 2 levels of control run 20 times each. We found Control Level 1's CV to be 7.0% and Control Level 2's CV was 2.6%. Our CV for Control Level 1 was higher than that established by the manufacturer. However, this is less than our preset 10% TEa. Furthermore, our 2 SD range is comparable to that established by the manufacturer. Using this same approach for the λ FLC assay, we found Control Level 1's CV to be 2.3% and Control Level 2's CV was 1.5%. Both CVs were comparable to manufacturer's reported precision for the λ assay (Control Level 1 CV, 3.9%; Control Level 2 CV, 1.3%; see Diazyme Human λ FLC assay product insert).
A quantitative comparison of the Beckman Coulter DxC-Diazyme platform to the Cobas Integra-Freelite platform indicated that there was a negative bias between the 2 κ assays ( Fig. 2A) , but using a qualitative approach to distinguish normal and abnormal values indicated 100% concordance (Fig. 3A) . A large positive bias was observed Verification of FDA-Approved Free Light Chain Assays ARTICLES between the 2 λ assays, and concordance for normal values was 95%, and 75% for abnormal values (Fig. 2C, Fig. 3B ). The 2 discordant samples that were abnormal for Freelite but normal for Diazyme averaged 1.19 mg/L (4.3%) below the Diazyme upper RR cutoff. The 1 discordant sample that was normal for Freelite but abnormal for Diazyme was 1.9 mg/L (7.2%) below the Freelite upper RR cutoff. For the κ/λ FLC ratio, of the 9 negative samples that were not concordant during method comparison, 4 of them averaged 0.10 (6.1%) above the upper RR cutoff for the Freelite FLC ratio (RR, 0.26 -1.65; Table 2 ). The other 5 discordant samples averaged 0.10 (5.7%) below the upper RR cutoff for the Diazyme FLC ratio (RR, 0.22-1.74; Table 2 ). The bias observed between the κ and λ assays on both platforms was expected, considering that we are making comparisons between 2 different assays designed by 2 different manufacturers, using 2 different antibodies, and running on 2 different platforms.
Recently, Smith and Wu (5) evaluated the use of the Diazyme assay on the Siemens Advia 1880 analyzer. In addition to reporting precision of the κ and λ assays, they performed a study to determine their RR. They reported a 99% concordance rate for κ FLC, and discordant samples were close to the upper limit of the RR, but within the 10% cutoff limit for assay imprecision. The concordance for λ FLC was 90% using the manufacturer's suggested RR. However, Smith and Wu opted for increasing the upper limit of the RR from 27.69 mg/L to 32.0 mg/L, which resulted in a 94% concordance rate. In our RR study, overall concordance for Diazyme κ FLC assay was 95%, and the only discordant sample was <10% from the upper cutoff limit for the assay. For λ FLC, concordance was 100%. For the κ/λ RR verification, 5 samples had discordant results between the different manufacturer's RRs. Two of the 5 samples had values averaging 0.12 below the Diazyme κ/λ upper RR cutoff (Table 2 ) and 3 samples had values averaging 0.13 below the Freelite κ/λ upper RR cutoff ( Table 2) . On the whole, these averaged <10% imprecision from the upper RR cutoff of both manufacturers' suggested κ/λ FLC RRs. Similar to Smith and Wu (5), all discordant samples were close to the upper limit of the RR. We suggest that further diagnostic workup including serum protein electrophoresis, serum immunofixation, hematological assessment, proteinuria, creatinine and eGFR evaluation, and biopsy is needed when monitoring a patient's condition, as a normal FLC ratio does not rule out the presence of other diseases such as AL amyloidosis (6) . In MM, diagnosis usually relies on serum/urine protein electrophoresis, serum/urine immunofixation electrophoresis, bone marrow biopsy, and imaging in addition to FLC analysis (7) .
FLCs can also be used to monitor progression of disease or treatment response (8) . In this instance, intraindividual changes in FLC are more important than a population-based RR. It has been shown with the Freelite FLC assays that intraindividual variation is low in healthy subjects (CVs <2.5% for κ and λ FLCs, as well as κ/λ FLC ratio) (4). Thus, although we see differences in our RR verification results vs what has been suggested by Diazyme, intraindividual variation is low in healthy subjects.
We conclude the Diazyme κ and λ FLC assays when run on the Beckman-Coulter DxC analyzer exhibit excellent precision and accuracy and are comparable to the Freelite assays on the Roche Cobas Integra analyzer. 
